カテゴリ： Global Markets Direct, 医療/バイオ

バッテン病治療薬市場：パイプラインレビュー（2020年上半期）

◆英語タイトル：Batten Disease - Pipeline Review, H1 2020
◆商品コード：GDATA20MY0797
◆発行会社（リサーチ会社）：Global Markets Direct
◆発行日：2020年2月28日
◆ページ数：92
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆調査対象地域：グローバル
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,000 ⇒換算￥216,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD4,000 ⇒換算￥432,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD6,000 ⇒換算￥648,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
※Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

 【レポートの概要】

Batten Disease – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Batten Disease – Pipeline Review, H1 2020, provides an overview of the Batten Disease (Central Nervous System) pipeline landscape.

Batten disease, a rare genetic disorder, belongs to a group of progressive degenerative neurometabolic disorders known as the neuronal ceroid lipofuscinoses. Symptoms of Batten disease usually become apparent between five and 15 years of age. Symptoms include vision loss, lack of muscle coordination, mental retardation or decreasing mental function, emotional disturbances, seizures, muscle spasms, deterioration of muscle tone and movement problems.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Batten Disease – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Batten Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Batten Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Batten Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 16 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 2 molecules, respectively.

Batten Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Batten Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Batten Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Batten Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Batten Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Batten Disease (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Batten Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Batten Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Batten Disease – Overview
Batten Disease – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Batten Disease – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Batten Disease – Companies Involved in Therapeutics Development
Abeona Therapeutics Inc
Amicus Therapeutics Inc
Blue Turtle Bio Technologies Inc
Circumvent Pharmaceuticals Inc
Collaborations Pharmaceuticals Inc
Exicure Inc
Polaryx Therapeutics Inc
Recursion Pharmaceuticals Inc
RegenxBio Inc
Retrotope Inc
Seneb BioSciences Inc
Spark Therapeutics Inc
Theranexus SAS
Xonovo Inc
Batten Disease – Drug Profiles
(gemfibrozil + tretinoin) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABO-201 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABO-202 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATGTX-502 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBDF-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DUOC-01 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gemfibrozil – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate CLN1 for Batten Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate CLN6 for Batten Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate CLN6 for Batten Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate CLN6 for Batten Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate CLN8 for Batten Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Palmitoyl Protein Thioesterase 1 for Batten Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate TPP1 for Batten Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate TPP1 for Batten Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INI-0602 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides for Neurology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-300 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Palmitoyl-Protein Thioesterase-1 Replacement for Batten Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGX-181 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RT-001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RT-002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Batten Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Batten Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Batten Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDC42 for Batten Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNB-4050 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPKTPP-1 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XN-001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Batten Disease – Dormant Projects
Batten Disease – Discontinued Products
Batten Disease – Product Development Milestones
Featured News & Press Releases
Jan 20, 2020: Polaryx Therapeutics receives IND approval for PLX-200 From the FDA for the treatment of late infantile neuronal ceroid lipofuscinosis
Oct 17, 2019: REGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual Congress
Jun 18, 2019: Abeona Therapeutics receives FDA fast track designation for ABO-202 AAV9 gene therapy in CLN1 disease
May 21, 2019: Abeona Therapeutics announces FDA clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease
Apr 15, 2019: Abeona Therapeutics to present data for ABO-202 in CLN1 disease at the American Society of Gene and Cell Therapy Annual Meeting
Jan 31, 2019: Spark Therapeutics announces presentation of preclinical data in CLN2 disease at 15th annual WORLDSymposium
Jan 31, 2019: REGENXBIO receives Rare Pediatric Disease Designation for RGX-181 Gene Therapy for the Treatment of CLN2 Form of Batten Disease
Dec 06, 2018: Abeona Therapeutics provides update on Infantile Batten Disease drug candidate ABO-202 at 2018 R&D Day
Nov 14, 2018: FDA grants Orphan Drug Designation to RGX-181 gene therapy for the treatment of CLN2 form of Batten disease
Sep 03, 2018: Regenxbio adds new neurodegenerative candidate to pipeline
Aug 30, 2018: REGENXBIO Announces Pipeline Expansion With RGX-181 Gene Therapy For CLN2 Form Of Batten Disease
Apr 20, 2018: Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
Mar 15, 2018: Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease
Feb 12, 2018: Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease
Dec 11, 2017: Polaryx Therapeutics Receives Orphan Drug Designation From the US FDA for the Treatment of Neuronal Ceroid Lipofuscinoses With PLX-100
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Batten Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Batten Disease - Pipeline by Abeona Therapeutics Inc, H1 2020
Batten Disease - Pipeline by Amicus Therapeutics Inc, H1 2020
Batten Disease - Pipeline by Blue Turtle Bio Technologies Inc, H1 2020
Batten Disease - Pipeline by Circumvent Pharmaceuticals Inc, H1 2020
Batten Disease - Pipeline by Collaborations Pharmaceuticals Inc, H1 2020
Batten Disease - Pipeline by Exicure Inc, H1 2020
Batten Disease - Pipeline by Polaryx Therapeutics Inc, H1 2020
Batten Disease - Pipeline by Recursion Pharmaceuticals Inc, H1 2020
Batten Disease - Pipeline by RegenxBio Inc, H1 2020
Batten Disease - Pipeline by Retrotope Inc, H1 2020
Batten Disease - Pipeline by Seneb BioSciences Inc, H1 2020
Batten Disease - Pipeline by Spark Therapeutics Inc, H1 2020
Batten Disease - Pipeline by Theranexus SAS, H1 2020
Batten Disease - Pipeline by Xonovo Inc, H1 2020
Batten Disease - Dormant Projects, H1 2020
Batten Disease - Discontinued Products, H1 2020

【掲載企業】

Abeona Therapeutics Inc
Amicus Therapeutics Inc
Blue Turtle Bio Technologies Inc
Circumvent Pharmaceuticals Inc
Collaborations Pharmaceuticals Inc
Exicure Inc
Polaryx Therapeutics Inc
Recursion Pharmaceuticals Inc
RegenxBio Inc
Retrotope Inc
Seneb BioSciences Inc
Spark Therapeutics Inc
Theranexus SAS
Xonovo Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer
★医療情報レポート[バッテン病治療薬市場：パイプラインレビュー（2020年上半期）]についてメールでお問い合わせはこちら

※関連の医療情報レポート

  1. バッテン病治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0012 / Global Markets Direct / 2019年11月18日 / ...Batten Disease - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Batten Disease - Pipeline Review, H2 2019, provides an overview of the Batten Disease (Central Nervous System) pipeline landscape. Batten disease, a rare genetic disorder, belongs to a group of progressive degenerative neurometabolic disorders known as the neuronal ceroid lipofuscinoses. Symptoms of Batten disease usually become apparent between five and 15 years of age. Symptoms include vision loss, lack of muscle coordination, mental retardation or decreasing mental function, emotional disturbances, seizures, muscle spasms, deterioration of muscle tone and movement problems. Report Highlights...
  2. Nスルホグルコサミンスルホヒドロラーゼ治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0837 / Global Markets Direct / 2020年2月28日 / ...N Sulphoglucosamine Sulphohydrolase - Pipeline Review, H1 2020 Summary According to the recently published report 'N Sulphoglucosamine Sulphohydrolase - Pipeline Review, H1 2020'; N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) pipeline Target constitutes close to 9 molecules. N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - N-sulphoglucosamine sulphohydrolase is an enzyme encoded by the SGSH gene. This enzyme is involved in the lysosomal degradation of heparan sulfate. Mutations in this gene are associated with Sanfilippo syndrome A, one type of the lysosomal storage disease mucopolysaccaridosis III. The report 'N Sulphoglucosamine Sulphohydrolase...
  3. リソソームアルファグルコシダーゼ治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0704 / Global Markets Direct / 2020年1月14日 / ...Lysosomal Alpha Glucosidase - Pipeline Review, H1 2020 Summary Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Lysosomal alpha-glucosidase is an enzyme encoded by the GAA gene. It is essential for the degradation of glygogen to glucose in lysosomes. Defects in this gene lead to glycogen storage disease II or Pompe disease. Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) pipeline Target constitutes close to 17 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase...
  4. フラタキシンミトコンドリア治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0841 / Global Markets Direct / 2020年2月28日 / ...Frataxin Mitochondrial - Pipeline Review, H1 2020 Summary Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Frataxin Mitochondrial - Pipeline Review, H1 2020, outlays comprehensive information on the Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Frataxin is a...
  5. フェニルアラニン4ヒドロキシラーゼ治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0733 / Global Markets Direct / 2020年1月14日 / ...Phenylalanine 4 Hydroxylase - Pipeline Review, H1 2020 Summary Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) pipeline Target constitutes close to 9 molecules. The latest report Phenylalanine 4 Hydroxylase - Pipeline Review, H1 2020, outlays comprehensive information on the Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) - Phenylalanine 4 hydroxylase or Phenylalanine hydroxylase (PAH) is an enzyme that catalyzes the...
  6. レーバー先天性黒内障（LCA）治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0937 / Global Markets Direct / 2020年3月31日 / ...Leber Congenital Amaurosis (LCA) - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leber Congenital Amaurosis (LCA) - Pipeline Review, H1 2020, provides an overview of the Leber Congenital Amaurosis (LCA) (Genetic Disorders) pipeline landscape. Leber congenital amaurosis is an eye disorder that primarily affects the retina, which is the specialized tissue at the back of the eye that detects light and color. This condition is the most common cause of inherited blindness in childhood. Symptoms include vision loss, roving eye movements, deep-set eyes, developmental delay, epilepsy, and motor skill impairment. Report Highlights...
  7. 拡張型心筋症治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0650 / Global Markets Direct / 2020年1月14日 / ...Dilated Cardiomyopathy - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dilated Cardiomyopathy - Pipeline Review, H1 2020, provides an overview of the Dilated Cardiomyopathy (Cardiovascular) pipeline landscape. Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include Fatigue and weakness, Shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing, lack of appetite, sudden weight gain from fluid retention and swelling (edema) in legs, ankles and feet. Risk factors...
  8. 脳脊髄炎治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0793 / Global Markets Direct / 2020年2月28日 / ...Encephalomyelitis - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalomyelitis - Pipeline Review, H1 2020, provides an overview of the Encephalomyelitis (Central Nervous System) pipeline landscape. Encephalomyelitis is an inflammation of the brain and spinal cord. Encephalomyelitis can be caused by a variety of conditions that lead to irritation of the brain and spinal cord. Among the common causes of encephalomyelitis are viruses which infect the nervous tissues. Signs and symptoms include neck stiffness, headache, and fever. Treatment includes antibiotics and corticosteroids. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline...
  9. 不整脈治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0786 / Global Markets Direct / 2020年2月28日 / ...Arrhythmias - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Arrhythmias - Pipeline Review, H1 2020, provides an overview of the Arrhythmias (Cardiovascular) pipeline landscape. An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. Signs and symptoms include anxiety, weakness, dizziness, and light-headedness, fainting or nearly fainting, sweating, shortness of breath and chest pain. Treatment includes anti-arrhythmics and anticoagulants. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Arrhythmias - Pipeline...
  10. プロバブルATP依存性RNAヘリカーゼDDX58治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0829 / Global Markets Direct / 2020年2月28日 / ...Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H1 2020 Summary Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) pipeline Target constitutes close to 10 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The latest report Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H1 2020, outlays comprehensive information on the Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆